On Jan. 11, 2021, TheNew York Times posted an article about the virtues of fecal immunochemical testing relative to colonoscopy. The story, “A Colonoscopy Alternative Comes Home” [https://www.nytimes.com/ 2021/ 01/ 11/ health/ colonoscopy-health-home-testing.html] depicted colonoscopy as a comparatively risky procedure with few advantages over less invasive methods of testing for colorectal cancer. It also offered the speculation that financial factors— namely, greater reimbursement for endoscopy—was behind the general preference of gastroenterologists for colonoscopy over stool tests.
Trending
- AI Companion Tool Identifies Food Triggers Based on IBS Sensitivity Testing (CLP)
- British startup BoobyBiome raises €2.8 million for infant health with breast milk microbiome breakthrough (EU-Startups)
- Locum tenens: Reclaiming purpose, autonomy, and financial freedom in medicine (KevinMD)
- Getting Ahead of Gastrointestinal Cancer (Medscape)
- Can AI and Molecular Testing Outperform Colonoscopy? (The Pathologist)
- Precision Gastroenterology: Harnessing Personalized Medicine for Transformative Patient Care (ASGE)
- Transforming Colonoscopy: The Role of Mechanical Enhancements in Boosting Polyp Detection Rates (ReachMD)
- Health Insurance Premiums To Rise Well Above Inflation For Most Americans (Forbes)